



Victhom Human Bionics

Press release

For immediate release

VICTHOM DISCLOSES 2008 ANNUAL AND FOURTH QUARTER FINANCIAL RESULTS

Quebec (Canada), May 1, 2009 - Victhom Human Bionics Inc. (Victhom, TSX: VHB) today reported its 2008 fourth quarter and annual financial results.

“We feel that in 2008 we created the foundation needed to allow us to bring products from both of our divisions to the market and create a significant and profitable business”, said Mr. Normand Rivard, Acting President and CFO of Victhom. “The recently announced partnership agreement with Otto Bock will not only secure funding for the Neurobionix activities but also bring unique expertise and a worldwide distribution network to make the launch of our first neuromodulation product, the Neurostep[®], a success. Finally, the second generation of the POWER KNEE early commercial release at Walter Reed Army Medical Center by our Biotronix division’s partner Ossur has set the stage for a full commercial release expected by 2010”.

2008 Annual and Fourth Quarter Results

For the year ended on December 31, 2008, the Company recorded revenues of \$2,286,468 compared with \$2,271,600 in 2007, representing an increase of \$14,868 or 0.7%. For the fourth quarter of 2008, the Company recorded revenues of \$597,700 compared with \$580,908 in 2007, an increase of \$16,792 or 2.9%. The revenues are generated from non-refundable advance royalties for an amount of \$2,185,618 (\$2,215,134 in 2007), of support activities for an amount of \$51,302 (\$33,774 in 2007), and of other sources for an amount of \$49,548 (\$22,691 in 2007).

Research and development (R&D) expenses, before tax credits and grants, amounted to \$10,100,239 for the year ended on December 31, 2008, compared with \$8,513,547 for the same period in 2007, representing an increase of \$1,586,692 or 18.6%. For the fourth quarter of 2008, the R&D expenses, before tax credits and grants, amounted to \$2,736,976 compared with \$2,270,000 in 2007, an increase of \$466,976 or 20.6%. The increase can be explained by higher expenses related to the ongoing clinical trial and the development of the commercial version of the Neurostep[®].

For the year ended on December 31, 2008, general and administrative (G&A) expenses, net of non-cash stock-based compensation charges of \$67,727, amounted to \$2,361,344 compared with \$2,367,492 for the same period in 2007, representing a decrease of \$6,148 or 0.3%. For the fourth quarter 2008, the G&A expenses, net of non-cash stock-based compensation charges of \$8,394 amounted to \$626,595 compared with \$606,954 for the same period in 2007, an increase of \$19,641 or 3.2%. The decrease in annual G&A expenses is mainly due to staff reduction in administrative functions and lower administrative expenses that were partially offset by non-recurring professional fees related to investor relation activities.

The net loss, net of non-cash items of \$8,309,945, for the year ended on December 31, 2008, amounted to \$7,970,444 compared with a net loss, net of non-cash items of \$991,316, for the same period in 2007, which amounted to \$6,186,602, representing an increase of \$1,783,842 or 28.8%. The net loss, net of non-cash charges of \$3,583,515, for the fourth quarter ended on December 31, 2008, amounted to \$2,122,437 compared with a net loss, net of non-cash charges of \$817,616, for the same period in 2007, which amounted to \$1,620,020, an increase of \$502,417 or 31.0%. The increase in net loss, net of non-cash items, is mainly the result of higher R&D expenses related to the ongoing clinical trial and the development of the commercial version of the Neurostep®.

Financial Situation

For the year ended on December 31, 2008, the net decrease in cash and cash equivalents was \$11,324,198 compared with an increase of \$5,943,523 for the same period in 2007. The cash used in operating activities in 2008 was \$8,653,726 driven by the net loss (after adding back non-cash adjustments) of \$7,970,444, and by changes in working capital items of \$683,282. The Company expects to incur additional expenditures to complete the development and marketing of its products. We will therefore require additional financing in connection with our business strategies to fund our requirements in working capital.

On April 30, 2009, the Company announced the execution of a partnership agreement to establish a joint venture with Otto Bock HealthCare GmbH (“Otto Bock”) to develop and commercialize products currently being developed by Victhom’s Neurobionix division. Over the next 2 ½ years, Otto Bock will invest CAN\$ 30 million to fund the development of the Neurostep® System and products in other indications. The Company believes that with this transaction, which is subject to Company’s debenture holders and shareholders approval, it will have sufficient liquidity to fund its continuing operations.

On December 31, 2008, the number of common shares outstanding totaled 123,088,923 while 6,873,000 options were granted under the stock option plan and 25,964,942 share purchase warrants are in circulation pursuant to past unit offerings. The outstanding options and share purchase warrants are exercisable respectively at a weighted average exercise price of \$0.40 and \$0.76 per share.

About Victhom

Victhom discovers, develops and manufactures bionic devices involved in the treatment of a variety of physical and physiological dysfunctions. Victhom’s Neurobionix business unit focuses on the development and commercialization of technologies and products involving implantable devices that feature neurosensing and neurostimulation components, integrated with artificial intelligence. Victhom’s Biotronix business unit develops biomechatronic products to support or replace peripheral limbs in what is known as the orthotics and prosthetics market.

FORWARD-LOOKING STATEMENTS

Some of the statements made herein may constitute forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause Victhom's actual results, performance or achievements to be materially different from those expressed or implied by any of Victhom's statements. Actual events or results may differ materially. We disclaim any intention, and assume no obligation, to update these forward-looking statements.

- 30 -

Source: Victhom Human Bionics Inc.

For more information: Normand Rivard
Acting President & CFO
Victhom Human Bionics Inc.
Tel.: 418-872-5665
Fax: 418-872-6926
normand.rivard@victhom.com

www.victhom.com